In a randomized pilot trial of 39 adults, researchers found that participants receiving medically tailored meals or Noom regained about 3.6% of their body weight over four months after stopping GLP-1 therapy, compared with about 11% under usual care. These exploratory findings suggest structured support may slow early weight regain, but the small sample and short follow-up leave lasting benefits uncertain.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
